Show simple item record

dc.contributor.authorLund Hansen, Rebekka
dc.contributor.authorSchoedt Jørgensen, Tanja
dc.contributor.authorDreyer, Lene
dc.contributor.authorHetland, Merete L
dc.contributor.authorGlintborg, Bente
dc.contributor.authorAskling, Johan
dc.contributor.authorDi Giuseppe, Daniela
dc.contributor.authorJacobsson, Lennart T H
dc.contributor.authorWallman, Johan K
dc.contributor.authorNordstrom, Dan
dc.contributor.authorAaltonen, Kalle
dc.contributor.authorKristianslund, Eirik K
dc.contributor.authorKvien, Tore K
dc.contributor.authorProvan, Sella A
dc.contributor.authorGudbjornsson, Bjorn
dc.contributor.authorLove, Thorvadur J
dc.contributor.authorKristensen, L E
dc.date.accessioned2021-03-04T15:28:59Z
dc.date.available2021-03-04T15:28:59Z
dc.date.issued2021-01
dc.date.submitted2021-03
dc.identifier.citationLund Hansen R, Schoedt Jørgensen T, Dreyer L, Hetland ML, Glintborg B, Askling J, et al. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study. Rheumatology (Oxford, England). 2021;60(1):140-6.doi:10.1093/rheumatology/keaa237.en_US
dc.identifier.pmid32591790
dc.identifier.doi10.1093/rheumatology/keaa237
dc.identifier.urihttp://hdl.handle.net/2336/621682
dc.descriptionTo access publisher's full text version of this article click on the hyperlink belowen_US
dc.description.abstractObjectives: To assess secular trends in baseline characteristics of PsA patients initiating their first or subsequent biologic DMARD (bDMARD) therapy and to explore prescription patterns and treatment rates of bDMARDs from 2006 to 2017 in the Nordic countries. Methods: PsA patients registered in the Nordic rheumatology registries initiating any treatment with bDMARDs were identified. The bDMARDs were grouped as original TNF inhibitor [TNFi; adalimumab (ADA), etanercept (ETN) and infliximab (IFX)]; certolizumab pegol (CZP) and golimumab (GOL); biosimilars and ustekinumab, based on the date of release. Baseline characteristics were compared for the five countries, supplemented by secular trends with R2 calculations and point prevalence of bDMARD treatment. Results: A total of 18 089 patients were identified (Denmark, 4361; Iceland, 449; Norway, 1948; Finland, 1069; Sweden, 10 262). A total of 54% of the patients were female, 34.3% of patients initiated an original TNFi, 8% CZP and GOL, 7.5% biosimilars and 0.3% ustekinumab as a first-line bDMARD. Subsequent bDMARDs were 25.2% original TNFi, 9% CZP and GOL, 12% biosimilars and 2.1% ustekinumab. From 2015 through 2017 there was a rapid uptake of biosimilars. The total of first-line bDMARD initiators with lower disease activity increased from 2006 to 2017, where an R2 close to 1 showed a strong association. Conclusion: Across the Nordic countries, the number of prescribed bDMARDs increased from 2006 to 2017, indicating a previously unmet need for bDMARDs in the PsA population. In recent years, PsA patients have initiated bDMARDs with lower disease activity compared with previous years, suggesting that bDMARDs are initiated in patients with a less active inflammatory phenotype. Keywords: bDMARDs; international collaborations; prescription patterns; psoriatic arthritis; secular trends of inflammatory hallmarks.en_US
dc.description.sponsorshipNordForsk FOREUM OAK Foundationen_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.urlhttps://academic.oup.com/rheumatology/article/60/1/140/5863694en_US
dc.rights© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
dc.subjectbDMARDsen_US
dc.subjectinternational collaborationsen_US
dc.subjectprescription patternsen_US
dc.subjectpsoriatic arthritisen_US
dc.subjectsecular trends of inflammatory hallmarksen_US
dc.subjectSóríasisen_US
dc.subjectLíftæknilyfen_US
dc.subject.meshArthritis, Psoriaticen_US
dc.subject.meshBiological Productsen_US
dc.titleInflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.en_US
dc.typeArticleen_US
dc.identifier.eissn1462-0332
dc.contributor.department1Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen. 2Department of Rheumatology, Aalborg University Hospital, Aalborg. 3DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet. 4Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 5Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm. 6Department of Rheumatology & Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg. 7Department of Clinical Sciences Lund, Rheumatology, Lund University, Skane University Hospital, Lund, Sweden. 8ROB-FIN, Division of Medicine, Helsinki University Hospital and Helsinki University. 9Pharmaceuticals Pricing Board, Ministry of Social Affairs and Health, Helsinki, Finland. 10Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. 11Centre for Rheumatology Research (ICEBIO), University Hospital, Faculty of Medicine, University of Iceland. 12University of Iceland and Landspitali University Hospital, Reykjavik, Iceland.en_US
dc.identifier.journalRheumatology (Oxford, England)en_US
dc.rights.accessLandspitali Access - LSH-aðganguren_US
dc.departmentcodeRHE12
dc.source.journaltitleRheumatology (Oxford, England)
dc.source.volume60
dc.source.issue1
dc.source.beginpage140
dc.source.endpage146
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record